These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 26780119)
21. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration. Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193 [TBL] [Abstract][Full Text] [Related]
22. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Brantley MA; Edelstein SL; King JM; Plotzke MR; Apte RS; Kymes SM; Shiels A Eye (Lond); 2009 Mar; 23(3):626-31. PubMed ID: 18292785 [TBL] [Abstract][Full Text] [Related]
23. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization. Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251 [TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Chang W; Noh DH; Sagong M; Kim IT Mol Vis; 2013; 19():702-9. PubMed ID: 23559864 [TBL] [Abstract][Full Text] [Related]
25. The Impact of Cebatoriene D; Vilkeviciute A; Gedvilaite-Vaicechauskiene G; Duseikaite M; Bruzaite A; Kriauciuniene L; Zaliuniene D; Liutkeviciene R Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273697 [TBL] [Abstract][Full Text] [Related]
26. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T; Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy. Komuku Y; Iwahashi C; Gomi F Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935 [TBL] [Abstract][Full Text] [Related]
28. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Jirarattanasopa P; Ooto S; Nakata I; Tsujikawa A; Yamashiro K; Oishi A; Yoshimura N Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3663-72. PubMed ID: 22570352 [TBL] [Abstract][Full Text] [Related]
29. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration. Weingessel B; Mihaltz K; Vécsei-Marlovits PV Wien Klin Wochenschr; 2016 Aug; 128(15-16):560-5. PubMed ID: 25787216 [TBL] [Abstract][Full Text] [Related]
30. Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration. Shah AR; Williams S; Baumal CR; Rosner B; Duker JS; Seddon JM Am J Ophthalmol; 2016 Mar; 163():154-166.e8. PubMed ID: 26705092 [TBL] [Abstract][Full Text] [Related]
31. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. Nakai S; Matsumiya W; Miki A; Honda S; Nakamura M Jpn J Ophthalmol; 2019 Sep; 63(5):389-395. PubMed ID: 31376050 [TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis. Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831 [TBL] [Abstract][Full Text] [Related]
33. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Maguire MG; Ying GS; Jaffe GJ; Toth CA; Daniel E; Grunwald J; Martin DF; Hagstrom SA; JAMA Ophthalmol; 2016 Jun; 134(6):674-81. PubMed ID: 27099955 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238 [TBL] [Abstract][Full Text] [Related]
35. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab. Dikmetas O; Kadayıfcılar S; Eldem B Mol Vis; 2013; 19():2571-8. PubMed ID: 24367156 [TBL] [Abstract][Full Text] [Related]
36. Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis. Roshanshad A; Moosavi SA; Arevalo JF Ophthalmic Res; 2024; 67(1):358-386. PubMed ID: 38754401 [TBL] [Abstract][Full Text] [Related]
37. Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy. Park UC; Shin JY; Chung H; Yu HG BMC Ophthalmol; 2017 Dec; 17(1):241. PubMed ID: 29212537 [TBL] [Abstract][Full Text] [Related]
38. Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration. Lee B; Yoo G; Yun C; Oh J Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2163-2172. PubMed ID: 31367847 [TBL] [Abstract][Full Text] [Related]
39. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991 [TBL] [Abstract][Full Text] [Related]
40. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration. Arias L; Pujol O; Berniell J; Rubio M; Roca G; Castillo L; Acebes E Br J Ophthalmol; 2005 Mar; 89(3):312-5. PubMed ID: 15722311 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]